In a study published on August 2nd, a team of scientists from Johns Hopkins Bloomberg School of Public Health in Maryland and Brigham and Women’s Hospital in Massachusetts conclude that preliminary evidence shows an interchangeability between biosimilars and their reference tumor necrosis factor-α (TNF-α) inhibitor counterparts.

While this study only applies to TNF-α inhibitors, an associate professor in the Department of Epidemiology at the Bloomberg School and co-director of the Johns Hopkins Center for Drug Safety and Effectiveness commenting on the article says this is great news for the biosimilar field. “There is no question that greater competition in this market will benefit patients, prescribers and society in the long run.”

“Biologics are the wave of the future,” he says. “That’s where more and more of the pharmaceutical market is going in the years ahead.”

Stay tuned for more at Big Molecule Watch.